截至收盘，恒生港股通创新药指数上涨3.3%，中证港股通医药卫生综合指数上涨3%，中证创新药产业指数上涨1.6%，中证生物科技主题指数上涨1.4%，沪 深300医药卫生指数上涨1%。 中信建投证券表示，中国医药产业已迈入"创新兑现+全球布局"的关键阶段，人口与内需基数、全产业链制造能力构成核心支撑，企业积极探索多元化的出 海路径。展望2026年，可以重点关注创新商业化、全球化突破、政策优化带来的新增量及行业并购整合的机遇。 1.6% 生物科技ETF (NO] 器踪中证生物科技术频指数 3.0% 取标十儿酒胶迪医药 上一示宣情数 该指数聚焦港股医疗卫生行 业龙头,由50只医疗器械 、生物药品、化学药及其它 医药卫生行业的港股通股票 组成。 �H 该指数涨跌 创新药ETF易方达得 跟踪中证创新药产业指数 该指数聚焦A股创新药龙头, 由不超过50只主营业务涉 及创新药研发的公司股票 组成,汇聚A股创新药主力 车。 �日 该指数涨跌 该指数聚焦A股生物科技龙 头,由不超过50只业务涉 及基因诊断、生物制药、血 液制品及其它人体生物科技 的公司股票组成。 �日 该指数涨跌 医药 ETF ONLY 跟踪沪深300医药卫生指 ...

【导读】 11 月 21 日股票 ETF 市场净流入超 400 亿元，资金持续加仓 ETF 中国基金报记者 王思文 11 月 21 日（上周五）， A 股三大股指大幅回调，创业板指跌超 4% ，深证成指跌 3.41% ，上证指数跌 2.45% 。市场震荡回调，股票 ETF 迎来资金 " 抄底加仓 " 。 当日股票 ETF 资金净流入超 400 亿元。其中宽基 ETF 、人工智能 ETF 、券商 ETF 为 " 吸金 " 大户。 宽基板块获大举加仓 Wind 数据显示，截至 11 月 21 日，全市场 1262 只股票 ETF （含跨境 ETF ）总规模为 4.47 万亿元。规模缩水主要受大盘下跌影响。 记者按照区间成交均价测算发现， 11 月 21 日股票 ETF 整体净流入资金高达 407.57 亿元， " 抄底资金 " 逢低加仓。 宽基板块 " 吸金 " 十分显著。具体来看，跟踪沪深 300 指数的 ETF 单日净流入金额达 48.9 亿元、跟踪中证 500 指数的 ETF 净流入金 额达 39 亿元、跟踪科创板 50 指数的 ETF 净流入金额达 38.6 亿元、跟踪创业板指数的 ETF 净流入金额达 ...

债权类ETF成资金避风港。 作者 | 市值风云基金研究部 编辑 | 小白 各位老铁大家好，这里是市值风云基金研究部ETF栏目，会在每周末发布ETF基金最新的市场数据和相应指数的估值数据。今天为第八十八期。 周评总共分为3大榜单。 行业中，光伏产业大跌11.3%，领跌两市，新能源汽车大跌8.3%，港股通互联网、国证芯片、中证钢铁、有色金属、创新药等板块跌超6%。 而中证银行、中证消费、中证军工、中证传媒、家用电器相对抗跌。 下跌并不可怕，我们得留有子弹抄底。从市盈率和市净率估值水平，各大指数基本上都有显著下降，下周如果继续下跌，或许是给抄底的机会。 指数估值天梯主要发布指数的ROE、PE和PB值，当前位置与近十年相比处于低估或高估，并且提供指数当前处于历史的分位数据。 ETF上涨"英雄"榜主要发布当周规模大于5亿元的ETF的涨幅前二十名。 份额增幅榜主要看当周规模超5亿元的ETF份额增加幅度前二十名。 指数估值"天梯"榜 本周市场大跌，投资者一片哀嚎。创业板指大跌超6%，领跌宽基指数，中证500、中证1000和科创50均跌逾5%。 | | | | | | 重要行业指数估值"天梯" 榜第八十八期(2025.11. ...

| 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-11-19 | 136.84万 | 5.53亿 | | | 2025-11-18 | -455.19万 | 5.51亿 | | | 2025-11-17 | 4544.78万 | 5.56亿 | | | 2025-11-14 | -558.47万 | 5.10亿 | | | 2025-11-13 | -2821.10万 | 5.16亿 | | 融券方面，当日融券卖出41.62万股，融券偿还10.5万股，融券净卖出31.12万股，融券余量2798.09万 股，近3个交易日已连续净卖出累计60.07万股。 证券之星消息，11月19日，医药ETF（512010）融资买入1.56亿元，融资偿还1.55亿元，融资净买入 136.84万元，融资余额5.53亿元。 | 交易日 | 两融余额(元) | 余额变动(元) | 变动幅度 | | --- | --- | --- | --- | | 2025-11-19 | 5.64亿 | 146.46万 | 0.26% | | 2025-11 ...

证券之星消息，11月19日，医药ETF（159929）融资买入770.46万元，融资偿还650.71万元，融资净买 入119.76万元，融资余额7749.25万元，近3个交易日已连续净买入累计305.88万元，近20个交易日中有 14个交易日出现融资净买入。 | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-11-19 | 119.76万 | 7749.25万 | | | 2025-11-18 | 131.17万 | 7629.49万 | | | 2025-11-17 | 54.95万 | 7498.32万 | | | 2025-11-14 | -150.31万 | 7443.37万 | | | 2025-11-13 | 1.52万 | 7593.68万 | | 融券方面，当日无融券交易。 融资融券余额7749.25万元，较昨日上涨1.57%。 | 交易日 | 两融余额(元) | 余额变动(元) | 变动幅度 | | --- | --- | --- | --- | | 2025-11-19 | 7749.25万 | 1 ...

Core Viewpoint - The Hong Kong pharmaceutical sector showed strong performance in the morning session, with various indices reflecting significant gains, indicating a positive market sentiment towards innovative drug companies and the broader healthcare industry [1]. Group 1: Index Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 4.3% [1]. - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 3.3% [1]. - The CSI Innovative Drug Industry Index saw a rise of 1.9% [1]. - The CSI Biotechnology Theme Index grew by 1.4% [1]. - The CSI 300 Pharmaceutical and Health Index climbed by 1.3% [1]. Group 2: Fund Inflows - The Hang Seng Innovative Drug ETF (159316) attracted a total of 1.4 billion yuan in inflows over the past month [1]. Group 3: Index Valuation Metrics - The rolling price-to-earnings (P/E) ratio for the CSI Biotechnology Theme Index is currently at 58.0 times, with a valuation percentile of 70.7% since its inception in 2015 [5]. - The rolling P/E ratio for the CSI 300 Pharmaceutical and Health Index stands at 31.3 times, with a valuation percentile of 49.3% since its inception in 2007 [7].

Group 1 - The core viewpoint of the report emphasizes the effectiveness of grid trading strategies in volatile markets, allowing investors to profit from price fluctuations without predicting market trends [4][12]. - The report identifies suitable characteristics for grid trading targets, including low trading costs, good liquidity, and significant volatility, suggesting that equity ETFs are appropriate for this strategy [4][12]. Group 2 - The report highlights the focus on specific ETFs for grid trading strategies, including the Military Industry ETF (512710.SH), which is expected to benefit from a new procurement cycle driven by the "14th Five-Year Plan" and increased defense budget [4][13]. - The Pharmaceutical ETF (512010.SH) is noted for its strong pipeline of innovative drugs, with China holding the second-largest number of drug development projects globally, and the potential for accelerated commercialization as domestic policies support innovation [5][16]. - The Hang Seng New Economy ETF (513320.SH) is positioned to capture the benefits of China's industrial upgrade and technological development, aligning with the "14th Five-Year Plan" goals [6][18].

Group 1 - The article discusses the potential investment opportunities in ETFs related to military, pharmaceutical, and new economy sectors, driven by China's strategic planning and budget allocations [3][4][10]. - The military sector ETF (512710.SH) is expected to benefit from China's defense budget increase to 1.81 trillion yuan in 2025, a 7.2% year-on-year growth, although still below the global average as a percentage of GDP [3][4]. - The pharmaceutical ETF (512010.SH) is positioned to capitalize on the unprecedented support for innovative drug development in China, with a significant increase in the number of drug pipelines and licensing agreements, reaching over 66 billion USD in total licensing amounts in the first half of 2025 [7][8]. Group 2 - The Hang Seng New Economy ETF (513320.SH) aims to leverage China's push for high-level technological self-reliance and the ongoing global economic easing, which creates a favorable environment for growth in sectors like internet, semiconductors, and renewable energy [10][11]. - The article highlights the strategic importance of the "14th Five-Year Plan" and the upcoming "15th Five-Year Plan" in shaping investment opportunities across these sectors, particularly in response to global geopolitical dynamics [3][10]. - The ETFs mentioned are expected to provide exposure to leading companies in their respective fields, benefiting from the anticipated improvements in industry fundamentals and government policies [4][7][10].

Group 1 - On November 3, the stock ETF market saw a net inflow of approximately 5.974 billion yuan, with significant contributions from industry-themed ETFs, particularly the brokerage sector, which attracted over 3.6 billion yuan in a single day [2][5] - The total scale of all stock ETFs in the market reached 4.64 trillion yuan as of November 3, with the Korean semiconductor ETF leading the market with a 4.62% increase [3][4] - The brokerage sector, referred to as the "bull market flag bearer," experienced a notable inflow of 1.767 billion yuan in ETF funds on the same day, with specific ETFs from Guotai Fund and Huabao Fund seeing substantial inflows [5][6] Group 2 - The industry-themed ETFs and Hong Kong market ETFs were the top gainers in terms of net inflow, with 3.675 billion yuan and 3.54 billion yuan respectively [5] - Several industry-themed ETFs, including those focused on banking, liquor, and chemicals, also saw significant inflows, with the banking ETF alone attracting 678 million yuan [5][6] - Despite the overall positive trend in industry-themed ETFs, broad-based ETFs experienced significant outflows, particularly the Shanghai Stock Exchange 50 ETF, which saw a net outflow of 1.195 billion yuan [7][8]

Core Viewpoint - The A-share market is experiencing a significant adjustment, with major indices declining and the Shanghai Composite Index falling below 4000 points, while stock ETFs have seen a net inflow of over 4.8 billion yuan on October 30 [2][3]. Fund Flow Summary - On October 30, stock ETFs recorded a net inflow of over 4.8 billion yuan, contributing to a total inflow of over 70 billion yuan in October, with significant inflows into sector-specific ETFs such as brokerage, Hang Seng Technology, and rare earths [3][5]. - The total scale of stock ETFs in the market reached 4.66 trillion yuan, with 1239 stock ETFs available [5]. - The top three stock ETFs by net inflow on October 30 were the Guotai Securities ETF, the GF Hong Kong Innovative Medicine ETF, and the Huabao Brokerage ETF, each with inflows exceeding 500 million yuan [5][7]. Sector-Specific Inflows - The medical sector led the inflows with a net inflow of 3.24 billion yuan, followed by the securities sector with 2.09 billion yuan, and the ChiNext with 1.12 billion yuan [5]. - The top 20 stock ETFs by net inflow included five medical-related ETFs and four brokerage-related ETFs, indicating strong interest in these sectors [6]. Outflows from Broad-based ETFs - On the same day, 27 stock ETFs experienced net outflows exceeding 1 billion yuan, with broad-based ETFs like the SSE 50, CSI 1000, and CSI 300 leading the outflows [10]. - The top three ETFs with the highest net outflows were the SSE 50 ETF (1.298 billion yuan), CSI 1000 ETF (736 million yuan), and three CSI 300 ETFs with a combined outflow of over 1 billion yuan [10][12]. Market Sentiment and Future Outlook - The overall sentiment in the market suggests a need for investors to focus on individual stock selection due to the previous broad market rally, with potential opportunities in quality growth and dividend value styles [10]. - Optimism remains regarding China's technology assets, particularly in AI, as the global AI industry accelerates, presenting ongoing investment opportunities [11].